2 Issues and Prospects

2 Issues and Prospects

2.1 This clinical trial included only 70 cases, a small sample size, so the results may be biased and require larger-scale follow-up studies to confirm.

2.2 Due to limitations in trial duration and funding, patient survival rates were not observed, so more comprehensive and in-depth research is needed in the future.

2.3 Due to ethical considerations and the doctor-patient relationship, this trial only used a blank control group and did not establish a group solely using Peishi Ruangan Xiaopi Pills, which to some extent reduced its persuasiveness.

2.4 This trial did not include immune indicators, nor did it thoroughly elaborate on the important role of traditional Chinese medicine in the body's responsiveness, which would have better demonstrated the advantages of the holistic view of traditional Chinese medicine.

References

[1] Teufel A, Marquardt JU, Galle PR, et al. Hepatocellular carcinoma: what's new [J]. Dtsch Med Wochenschr. 2012, 137(5): 210~213

[2] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma [J]. Lancet. 2012, 379(9822): 1245~1255

[3] Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis [J]. J Cancer Res Ther. 2011, 7(4): 463~475

[4] Flecken T, Schmidt N, Spangenberg HC, et al. Hepatocellular carcinoma from immunobiology to immunotherapy [J]. Z Gastroenterol. 2012, 50(1): 47~56

[5] Kojiro M. Pathology of hepatocellular carcinoma [J]. Molecular Genetics of Liver Neoplasia, 2011(2): 37~48

[6] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update [J]. Hepatology. 2011, 53(3): 1020~1022

[7] Mantovani A. Cancer: Inflaming metastasis [J]. Nature. 2009, 457(7225): 36~37

[8] Wu P, Dugoua JJ, Eyawo O, et al. Traditional Chinese Medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis [J]. Exp Clin Cancer Res, 2009, 28: 112

[9] Meng MB, Cui YL, Guan YS, et al. Traditional Chinese medicine plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma [J]. Altern Complement Med. 2008, 14(8): 1027~1042

[10] Chen PJ, Furuse J, Han KH, et al. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion [J]. Liver Int. 2010, 30(10): 1427~1438

Research on Pei Zhengxue's series of prescriptions and medicines

References

[11] Pei Zhengxue. Collection of Pei Zhengxue's Medical Experience. Gansu: Gansu Science and Technology Press, 2003: 27

[12] Dan Jinshu. The effect of Peishi Ruangan Xiaopi Pills on serum TNF-α and IFN-γ in H22-bearing mice. Gansu College of Traditional Chinese Medicine, 2011

[13] Tang Zhaoyou. Strategies for the efficacy of liver cancer treatment. Clinical Journal of Liver and Gallbladder Diseases, 2011, 27(4): 337~338

[14] Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning[J]. Nat Med, 2003, 9(4): 416~423

[15] Huang Xiuyan, Huang Zili, Xu Yonghua, et al. Experimental study on how palliative hepatectomy promotes the invasive potential of hepatocellular carcinoma. Chinese Journal of Clinical Physicians, 2011, 5(2): 479~481

[16] Yang Binghui, Xia Jinglin. Diagnostic and staging criteria for primary liver cancer. Chinese Journal of Liver Diseases, 2001, 9(6): 324

[17] Si Fuchun, et al. Analysis of TCM syndromes and medication usage for primary liver cancer over the past 30 years. World Journal of Integrated Chinese and Western Medicine, 2011, 6(1): 8~10

[18] National Pharmacopoeia Committee. Pharmacopoeia of the People's Republic of China (2005 Edition, Volume I). Beijing: Chemical Industry Press, 2005: 212

[19] Qiu Yongbo, et al. Progress in research on the chemical composition and pharmacological effects of Astragalus. Chinese Journal of Rehabilitation Medicine, 2011, 20(5): 435~436

[20] Xiao Shunhan, Ren Meiping, Liu Minghua, et al. The effect of Astragalus polysaccharides on IL-2, IL-6, IL-12, and TNF-α levels in tumor-bearing mice. Sichuan Journal of Physiological Sciences, 2009, 31(1): 7~8

[21] Wang Xin. Progress in pharmacological research and clinical application of danshenone. Guangming Traditional Chinese Medicine, 2011, 26(7): 1514~1517

[22] Li Juan, Shan Changmin, Zhao Yongde. Exploration of the mechanism by which Sparganium stoloniferum and Curcuma wenyujin combat rat liver fibrosis. Shandong Journal of Medicine, 2010, 50(37): 25~27

[23] Sun Jie, Wang Shao, Guo Bin, et al. Sparganium flavonoids against HeLa cervical cancer: reducing the ratio of dividing cells to induce apoptosis. Food Science, 2011, 32(1): 210~214

[24] Sun Jie, Wang Shao, Martin, et al. HPLC analysis of Sparganium flavonoid extracts and their components against HeLa cervical cancer. Northwest Botany Journal, 2010, 30(12): 2530~2535

[25] Li Xuechen, Zhang Tao, Wei Xiaodong. The inhibitory effect of Sparganium extract on H22 tumor-bearing mice. Heilongjiang Journal of Pharmaceutical Sciences, 2010, 33(5): 78

[26] Li Xun, Kong Fanzhi, Zhu Wanping. Progress in research on the anti-tumor effects of traditional Chinese medicine polysaccharides. Zhejiang Journal of Traditional Chinese Medicine, 2006, 41(2): 113

[27] Xu Donghui, Wang Sheng, Jin Jing, et al. Progress in research on the pharmacological effects of curcumin. Chinese Herbal Medicine, 2005, 36(11): 1737

[28] Yu Chenghao, Peng Cheng, Yu Congcong. Progress in research on the local medicinal materials of Sichuan, specifically Poria cocos. Time-Honored National Medicine and Pharmacy, 2008, 19(2): 388

[29] Liu Xiaoyu. Research on the chemical composition of volatile oil from Poria cocos. Master's thesis at Shenyang Pharmaceutical University, 2004

[30] Wen Wen, Zhang Peng. Modern pharmacological research and clinical application of frankincense and myrrh. Henan Traditional Chinese Medicine, 2009, 29(2): 204~206

[31] Xiao Juan, Liu Xuanming, Yan Donglan, et al. The inhibitory effect of frankincense volatile oil on the proliferation of human liver cancer cell line SMMC-7721 and its induction of apoptosis. Chinese Natural Medicines, 2007, 5(1): 68~73

[32] Liu Xiaoling, Wang Jin, Zhang Ling, et al. Experimental study on how Melia toosendan extract induces apoptosis in K562 cells. Chinese Herbal Medicine, 2010, 41(3): 426~431

[33] Wang Jin, Liu Xiaoling, Wang Peng, et al. The effect of Melia toosendan on the proliferation and apoptosis of K562 cells. Fourth Military Medical University Journal, 2009, 30(22): 2528~2532

[34] Editorial Committee of the Pharmacopoeia of the Ministry of Health of the People's Republic of China. Pharmacopoeia of the People's Republic of China. Beijing: People's Health Publishing House, 2005: 198

[35] Chen Ying, Tan Lingling, Cai Xia, Hu Zhenghai. Progress in research on the chemical composition of plants in the genus Bupleurum. China's Wild Plant Resources, 2006, 25(2): 5~7

[36] Motoo Y, Sawabu N. Antitumor effects of saikosaponins, baicalin, and baicalein on human hepatoma cell lines[J]. Cancer Lett, 1994, 86(1): 91~95

[37] Song Jinggui, Xiao Zhengming, Li Shipeng, et al. The inhibitory effect of Bupleurum extract on human liver cancer cells and mouse S-180 sarcoma. Shandong University of Traditional Chinese Medicine Journal, 2001, 25(4): 288~301

[38] Lu Dongyan, Ye Xiaowei. Application of quality of life assessment in the field of TCM anti-cancer treatment. Anhui College of Traditional Chinese Medicine Journal, 2011, 30(6): 70~72

[39] Zuo Fen, Lin Shengyou. Discussion on the application of quality of life assessment in evaluating the efficacy of TCM treatment for tumors. Yunnan Journal of Traditional Chinese Medicine and Herbal Medicine, 2008, 29(6): 55~57

[40] Gu Chaohui, Xie Liu, He Zhenhua. The impact of MVP chemotherapy regimen on the short-term quality of life of non-small cell lung cancer patients. Nursing Practice and Research, 2007, 4(1): 18~19

[41] Jiang Xiaofan, Shao Mingyi. Exploration of the application of quality of life scales in TCM clinical diagnosis and treatment. Jiangsu Traditional Chinese Medicine, 2008, 40(1): 12~14

[42] Feng Jiafu, Tu Zhiguang. Progress in research on serum enzymeology related to liver function. Medical Review, 2007, 13(3): 225~231

[43] Zhang Meiying, Wen Zhili, Xu Yanhua. The clinical significance of ALP, γ-GT, and CHE testing in chronic hepatitis B, cirrhosis, liver cancer, and biliary diseases. Nanchang University Journal (Medical Edition), 2012, 52(2): 34~36

Research on Pei Zhengxue's series of prescriptions and medicines

The Effects of Peishi Ruangan Xiaopi Pills on the Expression of Ang-2 in the Tumor and IL-12 in the Serum on H22 Bearing Mice

The Effects of Peishi Ruangan Xiaopi Pills on the Expression of Ang-2 in the Tumor and IL-12 in the Serum on H22 Bearing Mice

Qi Xueting